Childhood Obesity & Nutrition

Introduction: Diabetes is a chronic disease associated with many comorbidities and a higher risk of mortality. Patients are constantly in the lookout for Complementary and Alternative Medicines that are safe and efficacious for type 2 diabetes management. Objectives: The primary outcome was to evaluate the effect of GlucoLo Plus on HbA1c and the secondary outcome was to assess the effect on bodyweight and it’s innocuity.

Methodology: This double-blind randomised placebo-controlled trial evaluated the effects of daily GlucoLo Plus, a newly formulated all natural supplement for diabetes type 2 management.

Results: Of 64 individuals assessed for eligibility, 61 (mean HbA1c 6.98% [52.8 mmol/mol], mean age 67.3 years [SD 9·5], 26 [43%] women, mean diabetes duration 3.2 years, and mean body-mass index 27·9 kg/m2) were randomly assigned to GlucoLo Plus (n=32 [53%]), or placebo (n=28 [47%]). 1 participant was lost to follow up. At 12 weeks, GlucoLo Plus decreased HBa1c by 0.83% (P=0.0131) while placebo reduced it by 0.12% (p = 0.6151). The GlucoLo Plus arm had a mean 1.84 lbs weight loss while the placebo arm had a 0.21 lbs weight gain. The most frequent adverse events with GlucoLo Plus were mild and transient gastrointestinal events including nausea (9.3% vs 3.5%) and dyspepsia (15.6% vs 10.7%).

Conclusion: GlucoLo Plus significantly lowered the HbA1c, had a positive effect on bodyweight and had a minimal side effect profile. These results suggest that GlucoLo Plus could be an alternative and adjunct to type 2 diabetes in people who are reluctant to initiate or add new antidiabetic agents.